Patients and Methods: 85 patients with progressive multiple sclerosis (MS) were treated with autologous HSCT in 20 centers. 53 (62%) were female, median age was 39 (20-58) years, the median interval from diagnosis to transplant was 7.5 (1-33) years. Patients suffered from severe disease with a median EDSS score of 6.5 (4.5-8.5). Disease progression was documented in 79 of 81 evaluable cases, defined as deterioration by Ͼ1 point in the EDSS score or as active MRI at the time of transplant. Stem cell source was bone marrow in 6 and peripheral blood in 79. Stem cells were mobilized using cyclophosphamide combined with growth factors or growth factors alone. The high dose regimen included combination chemotherapy with or without antilymphocyte antibodies or with or without total body irradiation. The stem cell transplants were purged of lymphocytes in 50 patients. Median follow-up is 16 (2-60) months. Results: Treatment related mortality was 9 + 9%. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with disease progression. Some neurological deterioration during transplant was observed in 21 patients, this was transient in most but was associated with MS progression in 5 patients, 2 of them died. Neurological improvement by Ͼ 1 point in the EDSS score was seen in 18 (21%) patients. Confirmed progression-free survival was 68 + 14% at 3 years, 52 + 30%in patients with primary progressive MS but higher in patients with non-primary progressive MS 74 + 15% (NS). MRI data were available in 77 patients before transplant showing disease activity in 34%. Posttransplant MRI scan showed activity at any time in 5/60 (8%) evaluable cases. Conclusion: Autologous HSCT, despite mortality risks, shows promising results in stabilizing progressive MS.
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Conditioning regimen intensity and transplant related mortality in patients treated for autoimmune diseases by autologous stem cell transplantation (Abstract) J. Kashyap, J. Passweg, A. Fassas, A. Gratwohl, A. Tyndall (Basel, CH) Autologous stem cell transplantation (ASCT) has become established as a therapeutic modality worthy of further research for the treatment of selected patients with autoimmune disease (AD). As transplant related mortality (TRM) has been higher than expected, (9%) in early cohorts, this retrospective analysis was initiated in order to identify potential causes. Methods and Demographics: 290 patients who underwent ASCT at 69 centers in 21 countries between 1995 and 2000 were analyzed for TRM. Median age: 36 years (2-65), 66% female. AD categories: multiple sclerosis (n=94) systemic sclerosis (n=59), lupus (n=22), rheumatoid arthritis (n=41), juvenile inflammatory arthritis (n=34) or other diseases (n=40). Stem cell source: bone marrow 14%, peripheral blood 86%. Graft manipulation: purging, mainly by CD34 selection (with or without further T-cell depletion) 72%, unmanipulated 28%. Conditioning regimens were classified into three groups: high intensity 23%, {Cyclophosphamide (Cy) with radiation; Busulphan with Cy or other drugs}; intermediate intensity 47% {BEAM with or without ATG; Cy with ATG or other drugs}, and low intensity 30% {Cy alone or Fludarabine based}. Results: At a median follow-up of 1 year 32 patients had died; 7 from disease progression and 25 of TRM {toxicity (n=9), infections (n=16)}. Toxicity included interstitial pneumonitis, cardiac events and hemorrhage; infections included bacterial, fungal, viral and protozoal disease. TRM probabilities at 1 year were 19 + 10% (95% CI) with high intensity, 8 + 5% with intermediate intensity and 4 + 4% with low intensity conditioning regimens (p=0.003; log-rank test for trend). By multivariate analysis, TRM was significantly associated with conditioning intensity but not with disease type, purging, age or patient gender. There were associations between diagnoses and the conditioning regimen used however; e.g. BEAM was almost exclusively used in MS patients (54/62 receiving BEAM had MS and, conversely, 60% of MS patients received BEAM).
Conclusions: There appears to be a correlation between dose intensity of the conditioning regimen and TRM in patients with AD. Whether dose intensity results in a higher response rate is unknown so far. These data have to be interpreted cautiously as confounding by the disease type-conditioning regimen association cannot be excluded. Scrupulous attention to prophylaxis and treatment of infectious disease is essential.
